Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTCIHJA)

• DTT Name: Coagulation factor Xa (F10)
• Synonyms: Fxa; Factor Xa; F10; Activated coagulation factor X
• Gene Name: F10
• DTT Type: Successful target; [1]
• BioChemical Class: Peptidase
• UniProt ID: FA10_HUMAN
• TTD ID: T84631
• EC Number: EC 3.4.21.6
• Sequence:
  MGRPLHLVLLSASLAGLLLLGESLFIRREQANNILARVTRANSFLEEMKKGHLERECMEE
  TCSYEEAREVFEDSDKTNEFWNKYKDGDQCETSPCQNQGKCKDGLGEYTCTCLEGFEGKN
  CELFTRKLCSLDNGDCDQFCHEEQNSVVCSCARGYTLADNGKACIPTGPYPCGKQTLERR
  KRSVAQATSSSGEAPDSITWKPYDAADLDPTENPFDLLDFNQTQPERGDNNLTRIVGGQE
  CKDGECPWQALLINEENEGFCGGTILSEFYILTAAHCLYQAKRFKVRVGDRNTEQEEGGE
  AVHEVEVVIKHNRFTKETYDFDIAVLRLKTPITFRMNVAPACLPERDWAESTLMTQKTGI
  VSGFGRTHEKGRQSTRLKMLEVPYVDRNSCKLSSSFIITQNMFCAGYDTKQEDACQGDSG
  GPHVTRFKDTYFVTGIVSWGEGCARKGKYGIYTKVTAFLKWIDRSMKTRGLPKAKSHAPE
  VITSSPLK
• Function: Factor Xa is avitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
• KEGG Pathway: Complement and coagulation cascades (hsa04610)
• Reactome Pathway:
  Intrinsic Pathway of Fibrin Clot Formation (R-HSA-140837)
  Common Pathway of Fibrin Clot Formation (R-HSA-140875)
  Gamma-carboxylation of protein precursors (R-HSA-159740)
  Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus (R-HSA-159763)
  Removal of aminoterminal propeptides from gamma-carboxylated proteins (R-HSA-159782)
  Extrinsic Pathway of Fibrin Clot Formation (R-HSA-140834)
• BioCyc Pathway: MetaCyc:HS05000-MON

Molecular Interaction Atlas (MIA) of This DTT

11 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apixaban	DM89JLN	Thrombosis	DB61-GB90	Approved	[1]
BETRIXABAN	DM2C4RF	Venous thromboembolism	BD72	Approved	[2]
Certoparin sodium	DMUR94J	Deep vein thrombosis	BD71	Approved	[3]
Coagulation Factor IX	DM8HBJI	Haemophilia B	3B11.0	Approved	[4]
Danaparoid	DM6CLBN	Deep venous clot	BD71	Approved	[5]
DU-176b	DMCIJBH	Atrial fibrillation	BC81.3	Approved	[6]
Emicizumab	DM0AQ83	Factor VIII deficiency	3B10	Approved	[7]
Fondaparinux sodium	DMWS3FH	Deep vein thrombosis	BD71	Approved	[8]
Lmw heparin	DMJPD06	Coagulation defect	3B10.0	Approved	[3]
Nadroparin calcium	DMBNKST	Coagulation defect	3B10.0	Approved	[9]
Rivaroxaban	DMQMBZ1	Deep vein thrombosis	BD71	Approved	[10]

17 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Human coagulation factor X	DMYA6TR	Renal cell carcinoma	2C90	BLA submitted	[11]
MELAGATRAN	DM4W8RE	N. A.	N. A.	Phase 3	[12]
Mim8	DMX33ZR	Haemophilia A	3B10.0	Phase 3	[13]
PRT4445	DMVU8RW	Bleeding disorder	GA20-GA21	Phase 3	[11]
SSR-126517E	DMT71EX	Thrombosis	DB61-GB90	Phase 3	[11]
SR-123781A	DM5WQ2U	Venous thrombosis	BA43	Phase 2/3	[14]
Antistasin	DMDKRS3	Attention deficit hyperactivity disorder	6A05.Z	Phase 2	[15]
EP-217609	DMPC4EK	Thrombosis	DB61-GB90	Phase 2	[16]
GW-813893	DMH0C8J	Thrombosis	DB61-GB90	Phase 2	[11]
LY-517717	DM8OG0J	Thrombosis	DB61-GB90	Phase 2	[11]
BI-11634	DMKQHE5	Thrombosis	DB61-GB90	Phase 1	[11]
BIBT986	DMP70FI	Thrombosis	DB61-GB90	Phase 1	[17]
EP-42675	DMKR3GD	Thrombosis	DB61-GB90	Phase 1	[18]
GCC-4401	DMHMZC7	Thrombosis	DB61-GB90	Phase 1	[11]
R-1663	DM64U1Y	Coagulation defect	3B10.0	Phase 1	[11]
RG6512	DM8104I	Haemophilia A	3B10.0	Phase 1	[19]
SSR-128428	DMOJA7N	Thrombosis	DB61-GB90	Phase 1	[20]

19 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Darexaban maleate	DMC40SD	Acute coronary syndrome	BA41	Discontinued in Phase 3	[21]
Idraparinux	DM3SKAC	Thrombosis	DB61-GB90	Discontinued in Phase 3	[22]
Otamixaban	DMGOPMK	Angina pectoris	BA40	Discontinued in Phase 3	[22]
Valspodar	DMXRU9M	Acute myeloid leukaemia	2A60	Discontinued in Phase 3	[23]
Octopamine	DMLQVTJ	Thrombosis	DB61-GB90	Discontinued in Phase 2a	[24]
DX-9065	DMEQLC4	Coagulation defect	3B10.0	Discontinued in Phase 2	[11]
DX-9065a	DMIXUMZ	Angina pectoris	BA40	Discontinued in Phase 2	[25]
PD-348292	DMMYNKH	Thrombosis	DB61-GB90	Discontinued in Phase 2	[1]
R-68151	DM2NTJY	Psoriasis vulgaris	EA90	Discontinued in Phase 2	[26]
TAK-442	DMG4RFO	Thrombosis	DB61-GB90	Discontinued in Phase 2	[27]
AVE-3247	DMMPBZF	Thrombosis	DB61-GB90	Discontinued in Phase 1	[11]
DPC 423	DMR6INY	Thrombosis	DB61-GB90	Discontinued in Phase 1	[28]
EMD-503982	DMQH8L2	Thrombosis	DB61-GB90	Discontinued in Phase 1	[11]
JTV-803	DMXUH6W	Thrombosis	DB61-GB90	Discontinued in Phase 1	[11]
YM-75466	DMDJ2O5	Thrombosis	DB61-GB90	Discontinued in Phase 1	[11]
ZD-4927	DMQDNU1	Thrombosis	DB61-GB90	Discontinued in Phase 1	[11]
Draculin	DMX4KIT	Thrombosis	DB61-GB90	Terminated	[30]
Hirufaxin	DM784QJ	Thrombosis	DB61-GB90	Terminated	[11]
YM60828	DM7VGOC	N. A.	N. A.	Terminated	[15]

2 Preclinical Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CS-3030	DMK230A	Thrombosis	DB61-GB90	Preclinical	[11]
Trimidox	DMY8GDA	Solid tumour/cancer	2A00-2F9Z	Preclinical	[29]

35 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
1,2,3,4,6-penta-O-galloyl-beta-D-glucose	DMTK650	Discovery agent	N.A.	Investigative	[31]
3-chlorophenyl 2-oxo-2H-chromene-3-carboxylate	DMZ0F7E	Discovery agent	N.A.	Investigative	[32]
4-(4-Benzyloxy-3-methoxy-benzylamino)-benzamidine	DME3PUT	Discovery agent	N.A.	Investigative	[33]
5-desgalloylstachyurin	DM6TM1L	Discovery agent	N.A.	Investigative	[31]
Beta-Hydroxy Aspartic Acid	DMO8LPZ	Discovery agent	N.A.	Investigative	[34]
BMS-269223	DMZLE0U	Discovery agent	N.A.	Investigative	[35]
BMS-344577	DM9WRUG	Discovery agent	N.A.	Investigative	[35]
BMS-740808	DMQ24TI	Discovery agent	N.A.	Investigative	[36]
CASUARIIN	DM5E21C	Discovery agent	N.A.	Investigative	[31]
CI-1031	DMTKVDZ	Discovery agent	N.A.	Investigative	[37]
D-Pro-Phe-Arg chloromethyl ketone	DMRJQ8X	Discovery agent	N.A.	Investigative	[38]
DT-831j	DM3TMUK	Thrombosis	DB61-GB90	Investigative	[11]
EP-37	DMHN82B	Cerebrovascular ischaemia	8B1Z	Investigative	[11]
Gamma-Carboxy-Glutamic Acid	DMZMCT0	Discovery agent	N.A.	Investigative	[39]
GC-2107	DM46HAS	Thrombosis	DB61-GB90	Investigative	[11]
Lefaxin	DM0CEY3	Discovery agent	N.A.	Investigative	[15]
M55113	DMM5X8Z	Discovery agent	N.A.	Investigative	[40]
Molecule 11	DMZ6H1X	Discovery agent	N.A.	Investigative	[41]
Pedunculagin	DMKLRCX	Discovery agent	N.A.	Investigative	[31]
PhSO2-Gly-(Me-Gly)-Arg-(2-thiazole)	DMN0D14	Discovery agent	N.A.	Investigative	[42]
PRT-064445	DMOVE31	Bleeding disorder	GA20-GA21	Investigative	[11]
RAZAXABAN	DMPML15	Discovery agent	N.A.	Investigative	[36]
Recombinant coagulation factors	DMFAST4	Hemophilia	3B10.0	Investigative	[11]
Recombinant Factor X	DMX6LV3	Hemophilia	3B10.0	Investigative	[11]
SC-83157	DM96ATK	Discovery agent	N.A.	Investigative	[43]
SF303	DMH36A9	Discovery agent	N.A.	Investigative	[28]
SK509	DM73SC6	Discovery agent	N.A.	Investigative	[28]
SK549	DMK1OP2	Discovery agent	N.A.	Investigative	[44]
SK554	DMUTBZ8	Discovery agent	N.A.	Investigative	[15]
SN429	DMP4IJ6	Thrombosis	DB61-GB90	Investigative	[43]
Tellimagrandin II	DM60HU5	Discovery agent	N.A.	Investigative	[31]
YM-96765	DMPU5TC	Discovery agent	N.A.	Investigative	[45]
ZK-810388	DMNOWAQ	Discovery agent	N.A.	Investigative	[46]
ZK-813039	DMIC4HJ	Discovery agent	N.A.	Investigative	[46]
ZK-814048	DMCBV5F	Discovery agent	N.A.	Investigative	[46]

Molecular Expression Atlas (MEA) of This DTT

Disease Name	ICD 11	Studied Tissue	p-value	Fold-Change	Z-score
Renal cancer	2C82	Kidney	4.84E-02	-0.28	-0.9

References

• [1] Pfizer. Product Development Pipeline. March 31 2009.
• [2] Company report (Portola)
• [3] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [4] Haemophilia B: Christmas disease. Expert Opin Pharmacother. 2005 Aug;6(9):1517-24.
• [5] Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis. 2002 Nov 1;186(9):1270-6.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2359).
• [7] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [8] Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):218-24.
• [9] Serum zinc concentrations: contamination from laboratory equipment. JPEN J Parenter Enteral Nutr. 1979 May-Jun;3(3):179-81.
• [10] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [11] Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
• [12] Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7.
• [13] ClinicalTrials.gov (NCT05878938) Open-label Safety Study in Adults and Adolescents With Haemophilia A With and Without FVIII Inhibitors Switching Directly From Emicizumab Prophylaxis to NNC0365-3769 (Mim8) Prophylaxis. U.S.National Institutes of Health.
• [14] SR123781A, a synthetic heparin mimetic. Thromb Haemost. 2001 May;85(5):852-60.
• [15] Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32.
• [16] Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa.Blood.2012 Mar 8;119(10):2187-95.
• [17] Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa. J Thromb Haemost. 2006 Jul;4(7):1502-9.
• [18] EP42675, a synthetic parenteral dual-action anticoagulant: pharmacokinetics, pharmacodynamics, and absence of interactions with antiplatelet drugs. J Thromb Haemost. 2014 Jan;12(1):24-33.
• [19] Clinical pipeline report, company report or official report of Roche
• [20] Company report (Sanofi) (drug: FY2008)
• [21] The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4. Br J Clin Pharmacol. 2013 Feb;75(2):440-9.
• [22] Pharma & Vaccines. Product Development Pipeline. April 29 2009.
• [23] Non-hemostatic activity of coagulation factor Xa: potential implications for various diseases. Curr Opin Pharmacol. 2001 Apr;1(2):169-75.
• [24] Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026. J Thromb Haemost. 2009 Jul;7(7):1143-51.
• [25] DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins. Thromb Haemost. 2003 Jan;89(1):112-21.
• [26] Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as a factor Xa inhibitor II. Substituent effect on biological activities. Chem Pharm Bull (Tokyo). 2002 Sep;50(9):1187-94.
• [27] Clinical pipeline report, company report or official report of Takeda (2009).
• [28] The design and synthesis of noncovalent factor Xa inhibitors. Curr Top Med Chem. 2001 Jun;1(2):137-49.
• [29] Computer-aided design of a factor Xa inhibitor by using MCSS functionality maps and a CAVEAT linker search. J Mol Graph Model. 2003 Nov;22(2):105-14.
• [30] Expression of biological activity of draculin, the anticoagulant factor from vampire bat saliva, is strictly dependent on the appropriate glycosylation of the native molecule. Biochim Biophys Acta. 1998 Oct 23;1425(2):291-9.
• [31] Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade. J Nat Prod. 1998 Nov;61(11):1356-60.
• [32] 3,6-disubstituted coumarins as mechanism-based inhibitors of thrombin and factor Xa. J Med Chem. 2005 Dec 1;48(24):7592-603.
• [33] Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):817-22.
• [34] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [35] Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6882-9.
• [36] Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS... J Med Chem. 2007 Nov 1;50(22):5339-56.
• [37] Effects of ZK-807834, a novel inhibitor of factor Xa, on arterial and venous thrombosis in rabbits. J Cardiovasc Pharmacol. 2000 May;35(5):796-805.
• [38] Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. J Med Chem. 2008 Jun 12;51(11):3077-80.
• [39] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [40] Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitor. Chem Pharm Bull (Tokyo). 2001 Oct;49(10):1237-44.
• [41] Role of tissue factor pathway inhibitor in the regulation of tissue factor-dependent blood coagulation. Cardiovasc Drug Rev. 2002 Winter;20(1):67-80.
• [42] Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95.
• [43] Pharmacological intervention at disparate sites in the coagulation cascade: comparison of anti-thrombotic efficacy vs bleeding propensity in a rat model of acute arterial thrombosis. J Thromb Thrombolysis. 2002 Oct;14(2):113-21.
• [44] Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2. J Med Chem. 1999 Jul 29;42(15):2760-73.
• [45] Synthesis and biological activity of novel 1,4-diazepane derivatives as factor Xa inhibitor with potent anticoagulant and antithrombotic activity. Bioorg Med Chem. 2004 May 1;12(9):2179-91.
• [46] Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors. J Med Chem. 2007 Jun 28;50(13):2967-80.